VAERS Explorer
Back to explore

Report #2839962

Received May 8, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
Age unknown
State
MN
Recovered
Unknown
Vaccinated
Feb 21, 2025
Onset
Apr 2, 2025
Days to onset
40
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
HEPHEP B (HEPLISAV-B)DYNAVAX TECHNOLOGIES CORPORATION1——

Symptoms (2)

Extra dose administeredNo adverse event

Symptom narrative

Received HEPLISAV-B and then ENGERIX B; Initial report received on 11-Apr-2025. A nurse reported that a 40-year-old male received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization on 21-Feb-2025 and then received ENGERIX-B on 02-Apr-2025. No medical history or concomitant medications were reported. On 21-Feb-2025, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot number, expiration date, NDC number, route, and site not available)]. On 02-Apr-2025, 41 days after having been vaccinated with HEPLISAV-B, the patient received dose 2 of a hepatitis B vaccine [ENGERIX-B (lot number and expiration date not provided)]. The reporter was inquiring if another dose of HEPLISAV-B was required. No adverse reactions were reported. No additional information was reported. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.

Other medications

Engerix b